Across TCGA pan-cancer cohorts, IQCN mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IQCN data layer compared with 23 for mass-spec protein and 8 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher IQCN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IQCN expression acts as an unfavorable survival marker.
GBM are the cancer types where IQCN mass-spec protein most reproducibly stratifies survival.